Alector Provides Executive Leadership Update
Alector (NASDAQ: ALEC) announced key leadership changes with Giacomo Salvadore, M.D., appointed as the new Chief Medical Officer effective April 25, 2025, replacing Gary Romano, M.D., Ph.D., who is stepping down but will continue as an advisor. Dr. Salvadore, who joined Alector in 2023 as Senior Vice President of Clinical Development, brings over 15 years of neurology-focused clinical development experience.
The company highlighted its pipeline progress, including the pivotal INFRONT-3 Phase 3 trial of latozinemab in frontotemporal dementia, with topline data expected in Q4 2025, and the PROGRESS-AD Phase 2 trial of AL101 in early Alzheimer's disease, targeting enrollment completion by mid-2025. Alector plans to advance multiple early-stage programs into IND-enabling studies later in 2025, with first-in-human trials anticipated in 2026.
Alector (NASDAQ: ALEC) ha annunciato importanti cambiamenti nella leadership con Giacomo Salvadore, M.D., nominato nuovo Chief Medical Officer a partire dal 25 aprile 2025, che sostituisce Gary Romano, M.D., Ph.D., il quale si dimette ma continuerà come consulente. Il Dr. Salvadore, che è entrato in Alector nel 2023 come Senior Vice President of Clinical Development, porta con sé oltre 15 anni di esperienza nello sviluppo clinico focalizzato sulla neurologia.
L'azienda ha evidenziato i progressi del suo pipeline, inclusi il trial di fase 3 INFRONT-3 di latozinemab nella demenza frontotemporale, con dati preliminari attesi nel quarto trimestre del 2025, e il trial di fase 2 PROGRESS-AD di AL101 nella malattia di Alzheimer precoce, con l'obiettivo di completare l'arruolamento entro metà 2025. Alector prevede di avanzare diversi programmi in fase iniziale in studi abilitanti IND entro la fine del 2025, con i primi trial sull'uomo previsti per il 2026.
Alector (NASDAQ: ALEC) anunció cambios clave en el liderazgo con Giacomo Salvadore, M.D., nombrado nuevo Chief Medical Officer a partir del 25 de abril de 2025, reemplazando a Gary Romano, M.D., Ph.D., quien dejará el cargo pero continuará como asesor. El Dr. Salvadore, quien se unió a Alector en 2023 como Vicepresidente Senior de Desarrollo Clínico, aporta más de 15 años de experiencia en desarrollo clínico enfocado en neurología.
La compañía destacó el progreso de su pipeline, incluyendo el ensayo pivotal de fase 3 INFRONT-3 de latozinemab en demencia frontotemporal, con datos preliminares esperados para el cuarto trimestre de 2025, y el ensayo de fase 2 PROGRESS-AD de AL101 en la enfermedad de Alzheimer temprana, con el objetivo de completar la inscripción a mediados de 2025. Alector planea avanzar múltiples programas en etapas tempranas a estudios habilitantes de IND a finales de 2025, con ensayos en humanos anticipados para 2026.
Alector (NASDAQ: ALEC)는 2025년 4월 25일부터 새로운 최고 의학 책임자로 Giacomo Salvadore, M.D.를 임명하며 주요 리더십 변화를 발표했습니다. 그는 Gary Romano, M.D., Ph.D.를 대체하며, Romano는 사임하지만 계속해서 고문으로 활동할 예정입니다. Salvadore 박사는 2023년에 Alector에 합류하여 임상 개발의 수석 부사장으로 재직하며, 신경학 중심의 임상 개발 경험을 15년 이상 보유하고 있습니다.
회사는 중요한 INFRONT-3 3상 시험을 포함하여 latozinemab의 전두측두엽 치매에 대한 파이프라인 진행 상황을 강조했으며, 2025년 4분기에 주요 데이터가 예상됩니다. 또한 PROGRESS-AD 2상 시험에서 AL101의 초기 알츠하이머병에 대한 연구가 진행 중이며, 2025년 중반까지 등록 완료를 목표로 하고 있습니다. Alector는 2025년 말까지 여러 초기 단계 프로그램을 IND 승인 연구로 진행할 계획이며, 2026년에는 인간 대상 시험이 예상됩니다.
Alector (NASDAQ: ALEC) a annoncé des changements clés dans son équipe dirigeante avec la nomination de Giacomo Salvadore, M.D., en tant que nouveau Chief Medical Officer à compter du 25 avril 2025, remplaçant Gary Romano, M.D., Ph.D., qui se retire mais continuera en tant que conseiller. Le Dr Salvadore, qui a rejoint Alector en 2023 en tant que Vice-Président Senior du Développement Clinique, apporte plus de 15 ans d'expérience en développement clinique axé sur la neurologie.
L'entreprise a mis en avant les progrès de son pipeline, y compris l'
Alector (NASDAQ: ALEC) hat wichtige Führungswechsel bekannt gegeben, indem Giacomo Salvadore, M.D., ab dem 25. April 2025 als neuer Chief Medical Officer ernannt wurde. Er ersetzt Gary Romano, M.D., Ph.D., der zurücktritt, aber weiterhin als Berater tätig sein wird. Dr. Salvadore, der 2023 als Senior Vice President für klinische Entwicklung zu Alector kam, bringt über 15 Jahre Erfahrung in der klinischen Entwicklung mit Schwerpunkt Neurologie mit.
Das Unternehmen hob den Fortschritt seiner Pipeline hervor, einschließlich der entscheidenden INFRONT-3 Phase-3-Studie zu latozinemab bei frontotemporaler Demenz, mit den wichtigsten Daten, die im vierten Quartal 2025 erwartet werden, sowie der PROGRESS-AD Phase-2-Studie zu AL101 bei früher Alzheimer-Krankheit, die bis Mitte 2025 abgeschlossen sein soll. Alector plant, mehrere Programme in der frühen Phase bis Ende 2025 in IND-fähige Studien voranzutreiben, mit den ersten klinischen Studien am Menschen, die für 2026 erwartet werden.
- Pipeline advancement with two late-stage clinical candidates in development
- Multiple early-stage programs progressing toward IND-enabling studies
- Smooth leadership transition with experienced internal candidate
- Loss of experienced Chief Medical Officer Dr. Romano
--Giacomo Salvadore, M.D., appointed Chief Medical Officer--
--Gary Romano, M.D., Ph.D., to transition from Chief Medical Officer role--
SOUTH SAN FRANCISCO, Calif., March 28, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a late-stage clinical biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today announced that Gary Romano, M.D., Ph.D., has made the decision to step down from his role as Chief Medical Officer. Dr. Romano will continue to contribute to the company as an advisor following his transition. Giacomo Salvadore, M.D., has been appointed Chief Medical Officer effective April 25, 2025. Dr. Salvadore is an established industry executive physician and leader with more than 15 years of experience leading neurology-focused clinical development functions. He joined Alector in 2023 as Senior Vice President of Clinical Development and has a deep knowledge and understanding of the company’s pipeline and strategic priorities.
"Dr. Romano has played a pivotal role in shaping our clinical pipeline, driving progress across our programs, and helping position Alector for long-term success. His leadership and strategic vision have been instrumental in advancing our development efforts, and we are grateful for his dedication and impact,” said Arnon Rosenthal, Ph.D., Chief Executive Officer. “As we continue advancing toward key transformative milestones, we are pleased to appoint Dr. Salvadore as our new Chief Medical Officer. Giacomo’s extensive leadership and expertise in neurology and clinical development, combined with his strong knowledge of our programs, make him exceptionally well-suited to lead our clinical efforts. Under his leadership, we remain well-positioned to execute our strategy and advance first- or best-in-class therapies for patients with neurodegenerative diseases."
Alector currently has two late-stage clinical candidates and five research and preclinical programs, selectively supported by its proprietary blood-brain barrier technology platform, Alector Brain Carrier (ABC). The company remains on track to report topline data from the pivotal INFRONT-3 Phase 3 trial of latozinemab in frontotemporal dementia with a granulin gene mutation (FTD-GRN) in Q4 2025 and to complete enrollment in the PROGRESS-AD Phase 2 trial of AL101 in early Alzheimer’s disease by mid-2025. Additionally, Alector plans to advance multiple early-stage programs supported by ABC into IND-enabling studies later this year, with first-in-human trials expected in 2026.
"It has been a privilege to work alongside the talented team at Alector to advance a pipeline of therapies designed to address the urgent needs of patients with neurodegenerative diseases,” said Gary Romano, M.D., Ph.D., Chief Medical Officer. “I am confident that under Dr. Salvadore’s leadership, Alector’s clinical and preclinical programs will continue advancing toward meaningful potential breakthroughs. I look forward to supporting the transition and the company’s continued success."
About Dr. Salvadore
Giacomo Salvadore, M.D., joined Alector as Senior Vice President of Clinical Development in 2023, bringing more than 15 years of industry experience leading clinical development for neurology and psychiatry programs. At Alector, he drives the overall clinical development strategy for the company’s late-stage clinical portfolio as well as its research and preclinical portfolio.
Before joining Alector, Dr. Salvadore was the Vice President of Translational Medicine at Acadia Pharmaceuticals, where he led the overall strategy for the early development portfolio and guided the clinical development of multiple neurology and psychiatry programs. Prior to that, he spent more than a decade at Janssen Research & Development, where he held multiple leadership roles in clinical development, contributed to clinical strategies across neurology and psychiatry, and led biomarker strategy for central nervous system programs. Dr. Salvadore received his M.D. from the University of Rome, Tor Vergata, and is a trained psychiatrist. He completed a postdoctoral fellowship at the National Institutes of Health (NIH).
About Alector
Alector is a late-stage clinical biotechnology company focused on developing therapies to counteract the devastating progression of neurodegenerative diseases. Leveraging the principles of genetics, immunology and neuroscience, the company is advancing a portfolio of genetically validated programs that aim to remove toxic proteins, replace deficient proteins, and restore immune and nerve cell function. Supported by biomarkers, Alector’s product candidates seek to treat a range of indications, such as frontotemporal dementia, Alzheimer’s disease, and Parkinson's disease. The company is also developing Alector Brain Carrier (ABC), a proprietary blood-brain barrier platform, which is being selectively applied to its next-generation product candidates and research pipeline. ABC aims to enhance the delivery of therapeutics, achieve deeper brain penetration and efficacy at lower doses, and ultimately improve patient outcomes while reducing costs. Alector is headquartered in South San Francisco, California. For more information, please visit www.alector.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release include, but are not limited to, statements regarding our business plans, business strategy, product candidates, blood-brain barrier technology platform, research and preclinical pipeline, planned and ongoing preclinical studies and clinical trials, anticipated timing of and detail regarding release of data for INFRONT-3, anticipated timing for enrollment of PROGRESS-AD Phase 2, expected milestones, expectations of our collaboration with GSK, expectations of our interactions with regulatory authorities, and financial and cash guidance. Such statements are subject to numerous risks and uncertainties, including but not limited to risks and uncertainties as set forth in Alector’s Annual Report on Form 10-K filed for 2024, with the Securities and Exchange Commission (“SEC”), as well as the other documents Alector files from time to time with the SEC. These documents contain and identify important factors that could cause the actual results for Alector to differ materially from those contained in Alector’s forward-looking statements. Any forward-looking statements contained in this press release speak only as of the date hereof, and Alector specifically disclaims any obligation to update any forward-looking statement, except as required by law.
Alector Contacts:
Alector
Katie Hogan
202-549-0557
katie.hogan@alector.com
Argot Partners (media)
David Rosen
646-461-6387
alector@argotpartners.com
Argot Partners (investors)
Laura Perry
212-600-1902
alector@argotpartners.com
FAQ
When will Alector (ALEC) report topline data for its INFRONT-3 Phase 3 trial?
What is the timeline for Alector's (ALEC) PROGRESS-AD Phase 2 trial enrollment completion?
Who is the new Chief Medical Officer at Alector (ALEC) and when does the appointment take effect?
What are Alector's (ALEC) plans for early-stage programs in 2025-2026?
